Pharmacokinetics of glecaprevir/pibrentasvir in children with chronic HCV infection: interim analysis of part 2 of the DORA study [abstract 1551] | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Pharmacokinetics of glecaprevir/pibrentasvir in children with chronic HCV infection: interim analysis of part 2 of the DORA study [abstract 1551]

Jonas MM, Lon HK, Rhee S, Gilmour SM, Gonzalez-Peralta RP, Leung D, et al. Pharmacokinetics of glecaprevir/pibrentasvir in children with chronic HCV infection: interim analysis of part 2 of the DORA study [abstract 1551]. The Liver Meeting. Boston. Boston, Massachusetts; 2019.

Publication Type:

Conference Proceedings

Authors:

Jonas, MM; Lon, HK; Rhee, S; Gilmour, SM; Gonzalez-Peralta, RP; Leung, D; Ling, SC; et, al

Source:

The Liver Meeting. Boston, Boston, Massachusetts (2019)

Cited On:

HCV in Children

Export Citation:

RIS Format

Top